Trials / Recruiting
RecruitingNCT06424834
Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries
A Randomized Controlled Study of Targeted Medical Therapy Versus Placebo for Angina and Non- Obstructive Coronary Arteries: The MVP-ANOCA Study
- Status
- Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to learn if targeted medical therapy will improve symptoms and quality of life in patients with angina and non-obstructive coronary arteries compared to placebo, after the underlying cause of the chest pain has been ascertained by coronary function testing. Participants will be treated with either medications that target the underlying cause of their chest pain or placebo for 4 weeks after a drug titration phase of 1-3 weeks. They will be asked to complete a series of questionnaires to evaluate their quality of life at the beginning and end of the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amlodipine | Amlodipine taken once orally daily at a starting dose of 2.5mg, uptitrated to a maximum of 10mg if tolerated. |
| DRUG | Nebivolol | Nebivolol taken once orally daily at a starting dose of 5mg, uptitrated to a maximum of 20mg if tolerated. |
| DRUG | Placebo | Placebo taken once orally daily. |
Timeline
- Start date
- 2024-10-10
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2024-05-22
- Last updated
- 2024-11-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06424834. Inclusion in this directory is not an endorsement.